ライフサイエンスコーパス: invasive breast cancer

1 roups, similar to that seen in patients with invasive breast cancer.

2 opausal women with hormone-receptor-positive invasive breast cancer.

3 molog 1 (DACH1), whose expression is lost in invasive breast cancer.

4 6.9 years, 17,908 women were diagnosed with invasive breast cancer.

5 follow-up of 15 years, 4,484 women developed invasive breast cancer.

6 second most prevalent histologic subtype of invasive breast cancer.

7 itional four independent genetic datasets in invasive breast cancer.

8 ed molecular profiles indistinguishable from invasive breast cancer.

9 were classified as being at elevated risk of invasive breast cancer.

10 from noninvasive ductal carcinoma in situ to invasive breast cancer.

11 argin width in breast-conserving surgery for invasive breast cancer.

12 imaging increases detection of node-negative invasive breast cancer.

13 cases was associated with increased risk for invasive breast cancer.

14 ductal carcinoma in situ or stages I to III invasive breast cancer.

15 artum are associated with protection against invasive breast cancer.

16 a novel therapeutic target for treatment of invasive breast cancer.

17 ulates the worst prognosis for patients with invasive breast cancer.

18 We documented 4,734 cases of incident invasive breast cancer.

19 aluation of axillary status in patients with invasive breast cancer.

20 betes was associated with lower incidence of invasive breast cancer.

21 ce interval (CI), 1.2-4.2] increased risk of invasive breast cancer.

22 particularly prominent in the epithelium of invasive breast cancer.

23 n following partial mastectomy in women with invasive breast cancer.

24 observed in approximately 40% of women with invasive breast cancer.

25 a drop in overall survival of patients with invasive breast cancer.

26 mirror the molecular alterations observed in invasive breast cancer.

27 apeutic strategy for the treatment of highly invasive breast cancer.

28 reatments, but not all DCIS will progress to invasive breast cancer.

29 tential prognostic and therapeutic roles for invasive breast cancer.

30 Relative risks of developing invasive breast cancer.

31 Ten-year cumulative risk of invasive breast cancer.

32 eatment for women diagnosed with early stage invasive breast cancer.

33 stromal and immune microenvironment in HER2+ invasive breast cancer.

34 sociated with opposite histologic changes in invasive breast cancer.

35 nd metastasis formation in the PyMT model of invasive breast cancer.

36 tologic sections of 10 patients with stage 2 invasive breast cancers.

37 N-myc and STAT interactor) is compromised in invasive breast cancers.

38 e peripheral blood of patients with advanced invasive breast cancers.

39 expression within the stromal compartment of invasive breast cancers.

40 elative reduction in the annual incidence of invasive breast cancer (0.19% vs. 0.55%; hazard ratio, 0

41 eters squared, >35.0) (hazard ratio [HR] for invasive breast cancer, 1.58; 95% CI, 1.40-1.79).

42 Over an average of 10.5 years, 6,658 invasive breast cancers, 1,198 endometrial cancers, and

43 -7.3) was associated with lower incidence of invasive breast cancer (151 cases, 0.27% per year) compa

44 the 66 AA patients who developed subsequent invasive breast cancer, 16 (24.2%) developed TNBC compar

45 Of 373,563 women with invasive breast cancer, 268,675 (71.9%) were non-Hispani

46 f PSPHL using genomic DNA from AAW (199 with invasive breast cancer, 360 controls) and CW (invasive b

47 nvasive breast cancer, 360 controls) and CW (invasive breast cancer =589, 364 controls).

48 Of 496,488 women diagnosed with unilateral invasive breast cancer, 59.6% underwent breast-conservin

49 Of 496,488 women diagnosed with unilateral invasive breast cancer, 59.6% underwent breast-conservin

50 es, 1 slide per case), including 23 cases of invasive breast cancer, 73 ductal carcinoma in situ (DCI

51 fractures (56 fewer per 10 000 woman-years), invasive breast cancer (8 fewer per 10 000 woman-years),

52 fewer per 10 000 woman-years) and increased invasive breast cancer (8 more per 10 000 woman-years),

53 rson-years, were significantly increased for invasive breast cancer (9 more cases [95% CI, 1 to 19]),

54 better 5-year disease-specific survival for invasive breast cancer (97% vs 87% for patient- and phys

55 andard of care in the surgical management of invasive breast cancer, a benefit has not been demonstra

56 Current 10-year risks of invasive breast cancer after a diagnosis of ADH may be l

57 ormalized urinary cadmium concentration, and invasive breast cancer among 12,701 postmenopausal women

58 cancer, but we did see a 19% excess risk of invasive breast cancer among those with AF (adjusted haz

59 years of follow-up (1993-2010), 508 cases of invasive breast cancer and 1,050 comparison women were i

60 ean number of IVF cycles, 3.6), 839 cases of invasive breast cancer and 109 cases of in situ breast c

61 board-approved study included 125 women with invasive breast cancer and 274 age- and race-matched con

62 ogical studies, including 118 964 women with invasive breast cancer and 306 091 without the disease,

63 ntify methylation from 640 incident cases of invasive breast cancer and 741 controls.

64 Multivariable HRs for primary invasive breast cancer and 95% CIs were estimated by usi

65 s in 9% of DCIS and approximately 7% of both invasive breast cancer and all breast cancers in the U.S

66 rates (0.15% for DCIS and less than 0.1% for invasive breast cancer and all breast cancers).

67 be 9% for DCIS and approximately 7% for both invasive breast cancer and all breast cancers.

68 0.1% to the obligate overdiagnosis rates of invasive breast cancer and all breast cancers.

69 Verification of invasive breast cancer and benign without atypia diagnos

70 ogenous hormones improve risk prediction for invasive breast cancer and could help identify women who

71 ndpoint was the occurrence of breast cancer (invasive breast cancer and ductal carcinoma in situ), an

72 Medications reduced the incidence of invasive breast cancer and fractures and increased the i

73 ic features used to predict the prognosis of invasive breast cancer and may serve as a marker for stu

74 which postmenopausal women with HR-positive invasive breast cancer and no prior therapy for advanced

75 is the most commonly performed procedure for invasive breast cancer and often requires reexcision.

76 NAC use in patients with initially operable invasive breast cancer and potential impact on breast co

77 receptor (ER)-positive, lymph node-negative invasive breast cancer and to determine the relationship

78 agnosed with noninflammatory, nonmetastatic, invasive breast cancer and underwent surgery as initial

79 de methylation array analysis on 103 primary invasive breast cancers and 21 normal breast samples, us

80 romotes constitutive NF-kappaB activation in invasive breast cancers and activation of this pathway i

81 the 94 WA patients who developed subsequent invasive breast cancers and had complete biomarker data

82 Comparing risk factor associations between invasive breast cancers and possible precursors may furt

83 A-to-I RNA-edited form of Gabra3 only in non-invasive breast cancers and show that edited Gabra3 supp

84 ine whether WISP1 expression is increased in invasive breast cancer, and 3) to determine whether a ge

85 te (or type 1) overdiagnosis rates for DCIS, invasive breast cancer, and all breast cancers (DCIS plu

86 0%, 21%, and 22.5% at age 80 years for DCIS, invasive breast cancer, and all breast cancers, respecti

87 cancer, for ductal carcinoma in situ (DCIS), invasive breast cancer, and all breast cancers.

88 e surgeons' approach to surgical margins for invasive breast cancer, and changes in postlumpectomy su

89 n-progestin (stroke, coronary heart disease, invasive breast cancer, and pulmonary embolism), and ral

90 ptor-positive and estrogen receptor-negative invasive breast cancer, and the emergence of distinct pa

91 n human breast cancer cell lines and primary invasive breast cancers, and Cyclin D3 frequently exceed

92 ressed and amplified in approximately 15% of invasive breast cancers, and is the molecular target and

93 Kinetic data in invasive breast cancer are associated with the patient's

94 h anti-tumor immunity were obtained from the invasive breast cancer arm of the Cancer Genome Atlas st

95 ductal carcinoma in situ (DCIS) lesions and invasive breast cancers as well as with increased mortal

96 h increased DCIS incidence, the diagnosis of invasive breast cancer at earlier stages, and increased

97 ts diagnosed with a first primary unilateral invasive breast cancer at Kaiser Permanente Institute fo

98 ts diagnosed with a first primary unilateral invasive breast cancer at Kaiser Permanente Institute fo

99 a in situ (DCIS) components of biopsy-proven invasive breast cancer before surgery and (b) investigat

100 ing improves depiction of DCIS components of invasive breast cancers before surgery and is associated

101 iagnosed with incident localized or regional invasive breast cancer between 1988 and 2008; a subset o

102 We documented 2,866 incident cases of invasive breast cancer between 1991 and 2011.

103 who underwent surgery for primary unilateral invasive breast cancer between 2003 and 2008 were select

104 pliant protocol, 408 patients diagnosed with invasive breast cancer between 2004 and 2013 who underwe

105 o were 18 to 64 years old and diagnosed with invasive breast cancer between 2007 and 2009, linking ca

106 of 238726 adult patients diagnosed as having invasive breast cancer between 2010 and 2013 for whom th

107 premenopausal women who were diagnosed with invasive breast cancer between 26 and 47 years of age.

108 Among a convenience cohort of patients with invasive breast cancer, breast tumor and matched normal

109 ncreases in the detection of early-stage non-invasive breast cancer but no noteworthy change in the i

110 a diagnosis of an ipsilateral second primary invasive breast cancer, but prevention of these recurren

111 tyrosine kinase Pyk2 is highly expressed in invasive breast cancer, but the mechanism by which it po

112 gnalling cross talk has been demonstrated in invasive breast cancer, but their role in DCIS stem and

113 rea under the curve (AUC) for 5-year risk of invasive breast cancer by adding each hormone to the Gai

114 white woman in the United States developing invasive breast cancer by age 80 years is 11.3%.

115 We investigated risk factor associations for invasive breast cancer by method of detection within a s

116 sed imaging or targeted therapy, we screened invasive breast cancers by immunohistochemistry for the

117 0.98) at 14q24.1 (RAD51L1), for up to 46 036 invasive breast cancer cases and 46 930 controls from 39

118 ted case-control study in 621 postmenopausal invasive breast cancer cases and 621 matched controls in

119 tudy in the Nurses' Health Study, with 1,506 invasive breast cancer cases diagnosed after blood donat

120 Incident invasive breast cancer cases were confirmed by medical r

121 Between 1995 and 2008, 2482 invasive breast cancer cases were diagnosed among 57,403

122 During follow-up, a total of 5,483 invasive breast cancer cases were diagnosed.

123 rs of follow-up through June 30, 2007, 4,084 invasive breast cancer cases were diagnosed.

124 and 2001; median follow-up, 8.9 years; 1,905 invasive breast cancer cases).

125 e absence of both Nischarin and LKB1 from an invasive breast cancer cell line (MDA-MB-231) enhances m

126 Actopaxin phosphorylation is elevated in the invasive breast cancer cell line MDA-MB-231 compared wit

127 atic breast-231 cells, a prototypical highly invasive breast cancer cell line, to degrade the extrace

128 n factor 1 (ARF1) is overexpressed in highly invasive breast cancer cell lines and that epidermal gro

129 The highly invasive breast cancer cell lines, MDA-MB-231 and 4T1, e

130 Second, we stably overexpressed PLD2 in low-invasive breast cancer cells (MCF-7) with a biscistronic

131 Attachment of invasive breast cancer cells (MDA-MB-231) to human umbil

132 By contrast, primary cultures of invasive breast cancer cells convert glutamine to glutam

133 It was found that highly-invasive breast cancer cells exhibited greater deformabi

134 e show that depletion of ezrin expression in invasive breast cancer cells impairs both FA and invadop

135 ified stromal fibroblast-induced gene in non-invasive breast cancer cells is highly overexpressed in

136 own of plakoglobin in these low motility non-invasive breast cancer cells rearranged the actin filame

137 Reduction of DP103 expression in invasive breast cancer cells reduced phosphorylation of

138 The molecular mechanisms by which invasive breast cancer cells regulate this migratory pla

139 , either recombinant or secreted from highly invasive breast cancer cells, down-regulates the tumor s

140 colocalizes with cortactin to invadopodia of invasive breast cancer cells, where it mediates epiderma

141 Rac3 and promote invadopodial maturation in invasive breast cancer cells.

142 exhibited greater deformability than weakly-invasive breast cancer cells.

143 to force-dependent directional migration of invasive breast cancer cells.

144 o determine how MSCs affect the migration of invasive breast cancer cells.

145 he regulation of ARF1 and ARF6 activation in invasive breast cancer cells.

146 l adherens junctions after the attachment of invasive breast cancer cells.

147 volumetric imaging of fluorescent beads and invasive breast cancer cells.

148 the tumorigenic and metastatic potential of invasive breast cancer cells.

149 a is needed in patients with newly diagnosed invasive breast cancer, CNB is more sensitive than FNAB.

150 increased risk of estrogen receptor-positive invasive breast cancer compared with women who never wor

151 protein array data show that PEA15 levels in invasive breast cancers correlate with patient survival,

152 A total of 8,421 cases of invasive breast cancer developed in postmenopausal women

153 score greater than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior

154 total of 24 843 patients with stage I to III invasive breast cancer diagnosed between January 1, 2005

155 A cohort of 6,294 patients with invasive breast cancer diagnosed under 50 years of age a

156 emerging medical applications including non-invasive breast cancer diagnosis, cancer margin evaluati

157 signed to detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35

158 ted with increased survival in patients with invasive breast cancer, especially in patients with inva

159 102 women ages 20 to 49 years diagnosed with invasive breast cancer from 1990 to 2009.

160 with early-stage, hormone receptor-positive invasive breast cancer from 1998 to 2003.

161 Women diagnosed with invasive breast cancer from 2001 to 2008 in Stockholm, S

162 Observational study of women diagnosed with invasive breast cancer from 2004 to 2011 who were identi

163 y confirmed triple-negative operable primary invasive breast cancer from 360 sites in 37 countries.

164 Patients with a diagnosis of invasive breast cancer from January 2005 through Decembe

165 Main analyses included patients with invasive breast cancer from population- and hospital-bas

166 gery as their first therapeutic modality for invasive breast cancer from September 2003 to December 2

167 ages 18-years and older diagnosed with 2907 invasive breast cancers from January 2003 to December 20

168 20 to 45 years at the time of diagnosis with invasive breast cancer, from January 1, 2003, to Decembe

169 nd particularly as the surgical treatment of invasive breast cancer has changed.

170 es attenuated the association between AF and invasive breast cancer (HR = 1.01, 95% CI: 0.85, 1.20).

171 de use was strongly associated with incident invasive breast cancer (HR = 1.68, 95% CI: 1.33, 2.12) i

172 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cu

173 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).

174 increased after experience of an ipsilateral invasive breast cancer (HR, 18.1 [95% CI, 14.0-23.6]; P

175 mal growth factor receptor 2 (HER2)-positive invasive breast cancer (IBC) at risk for treatment failu

176 fective as tamoxifen in reducing the risk of invasive breast cancer (IBC) in postmenopausal women and

177 tion from ductal carcinoma in situ (DCIS) to invasive breast cancer (IBC) is a crucial step in breast

178 nts with histologically verified nonpalpable invasive breast cancer (IBC) or ductal carcinoma in situ

179 DCIS and patients with DCIS and synchronous invasive breast cancer (IBC).

180 case-control Carolina Breast Cancer Study of invasive breast cancer in 1,391 black (725 cases, 666 co

181 ted comparing the 10-year cumulative risk of invasive breast cancer in 955331 women undergoing mammog

182 se of hormonal contraception and the risk of invasive breast cancer in a nationwide prospective cohor

183 ith early-stage, estrogen receptor-positive, invasive breast cancer in the absence of additional prog

184 ment of DCIS could prevent the occurrence of invasive breast cancer in the future is not clear.

185 To study the progression of DCIS to invasive breast cancer in vivo, we introduced human DCIS

186 Analyzed were 117 invasive breast cancers in 117 patients.

187 Exemestane significantly reduced invasive breast cancers in postmenopausal women who were

188 fier is associated with indolent behavior of invasive breast cancers in women followed for 2 decades.

189 [95% CI, 1.11 to 1.23]) but no difference in invasive breast cancer incidence (adjusted OR, 1.00 [CI,

190 ne, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 post

191 Time-specific invasive breast cancer incidence rates and exploratory a

192 sessed long-term effects of oestrogen use on invasive breast cancer incidence, tumour characteristics

193 The data set of biopsy-proven invasive breast cancers included 74 (88%) ductal, eight

194 ears of follow-up, there were 1,851 incident invasive breast cancers, including 914 ER+ and 468 ER- c

195 The 10-y absolute risk of invasive breast cancer increased from 3,749 per 100,000

196 ent dietary risk factor for premalignant and invasive breast cancer is alcohol, whether consumed duri

197 An important clinical biomarker for invasive breast cancer is human epidermal growth factor

198 a in situ (DCIS)--a significant precursor to invasive breast cancer--is typically diagnosed as microc

199 -27)/HLA-A2 complex was exclusively found in invasive breast cancer, it could be a useful prognostic

200 strogen receptor alpha-negative (ERalpha(-)) invasive breast cancers, its role in ERalpha-positive (E

201 ing data from 4140 women with a diagnosis of invasive breast cancer made between 1995 and 2009.

202 Results: Among 7541 women with invasive breast cancer, median age at initial breast can

203 Among 7541 women with invasive breast cancer, median age at initial breast can

204 elial-stromal co-expression relationships in invasive breast cancer mostly represent self-loops, in w

205 improved risk prediction for postmenopausal invasive breast cancer (n = 437 patient cases and n = 77

206 ression profiling of human DCIS (n = 53) and invasive breast cancer (n = 51) to discover uniquely exp

207 We evaluated all invasive breast cancers (N = 641) that were systematical

208 We included 3,012 patients with invasive breast cancer newly diagnosed between 2001 and

209 in a population-based case-control study of invasive breast cancer newly diagnosed in 1992-1995.

210 Patients were women with clinical T1-T2 invasive breast cancer, no palpable adenopathy, and 1 to

211 e patients were women with clinical T1 or T2 invasive breast cancer, no palpable axillary adenopathy,

212 from 1980-2006, during which 3,398 incident invasive breast cancers occurred over 1.4 million person

213 Women with invasive breast cancer of 3 cm or greater undergoing NAC

214 February 4, 2016, patients with nonpalpable invasive breast cancer or DCIS visible on ultrasound wer

215 A total of 18437 women with invasive breast cancer or ductal carcinoma in situ were

216 9, 95% CI 0.29-0.81, p for trend = 0.01) and invasive breast cancer (OR = 0.63; 95% CI: 0.42, 0.93, P

217 cted in 61% of CW compared to 6% of AAW with invasive breast cancer (P < 0.0001); genotype frequencie

218 ative (P<0.05) and with triple negative (TN) invasive breast cancer (P<0.05).

219 l-stromal crosstalk plays a critical role in invasive breast cancer pathogenesis; however, little is

220 , Massachusetts, and New Hampshire (n=15,648 invasive breast cancer patients and 17,602 controls aged

221 and determine whether survival differed for invasive breast cancer patients based on hormone recepto

222 ome in a retrospective cohort of 146 primary invasive breast cancer patients.

223 1999 to 2002, women with completely excised invasive breast cancer (pT1-3a, pN0-1, M0) were enrolled

224 rs) with newly diagnosed HER2-negative early invasive breast cancer (radiological tumour size >20 mm,

225 Twenty-two patients with invasive breast cancer received (18)F-FDG (5 MBq/kg) 45-

226 Methods: Twenty-two patients with invasive breast cancer received (18)F-FDG (5 MBq/kg) 45-

227 , multicenter case-control study of incident invasive breast cancer, recruited women aged 35-64 years

228 Clinical outcomes were invasive breast cancer recurrence and new primary breast

229 point was disease-free survival (events were invasive breast cancer relapse, second primaries [contra

230 ession of ductal carcinoma in situ (DCIS) to invasive breast cancer remain largely unknown.

231 ession of ductal carcinoma in situ (DCIS) to invasive breast cancer remain poorly understood.

232 tcomes were coronary heart disease (CHD) and invasive breast cancer, respectively.

233 Obesity is associated with increased invasive breast cancer risk in postmenopausal women.

234 o were overweight and obese had an increased invasive breast cancer risk vs women of normal weight.

235 In the estrogen alone trial, the HR for invasive breast cancer risk was lower than 1 throughout

236 ial outdoor light at night may contribute to invasive breast cancer risk.

237 In invasive breast cancer specimens, Rictor expression was

238 how that S100A14 and HER2 are coexpressed in invasive breast cancer specimens,andthere is a significa

239 the deletion allele in AAW with and without invasive breast cancer suggests that this difference rep

240 from Medicare claims as having had incident invasive breast cancer surgery in 2003.

241 ive oestrogen alone had a lower incidence of invasive breast cancer than did those who received place

242 igher risk for transition to more aggressive invasive breast cancer than low-grade DCIS.

243 Among US women diagnosed with invasive breast cancer, the likelihood of diagnosis at a

244 nosis and that these lesions may progress to invasive breast cancer through a variety of evolutionary

245 Women who have large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory

246 Women who have large or locally advanced invasive breast cancer (tumor size T3/T4), inflammatory

247 The first estimation approach found that 271 invasive breast cancer tumors and 179 ductal carcinoma i

248 Women with invasive breast cancer undergoing partial mastectomy fro

249 006-2012) were used to identify females with invasive breast cancer undergoing planned mastectomy.

250 informed consent, 531 women with unilateral invasive breast cancer underwent dynamic contrast-enhanc

251 A total of 2206 women with 2220 invasive breast cancers underwent partial mastectomy and

252 The estimated OR for invasive breast cancer was 2.26 (95%CI, 1.90 to 2.69; P

253 g a diagnosis of ADH, the cumulative risk of invasive breast cancer was 2.6 (95% CI, 2.0-3.4) times h

254 tely 15 years of follow-up, the incidence of invasive breast cancer was 5.7%, and the incidence of co

255 Oncogenic transformation in invasive breast cancer was associated with an increase i

256 elevated risk for estrogen receptor-positive invasive breast cancer was associated with solvent expos

257 h whole-breast irradiation in stage I and II invasive breast cancer was considered for endorsement.

258 The gene expression signature in invasive breast cancer was consistent with WISP1 as a pa

259 Progression of xenografts to invasive breast cancer was dramatically increased by sup

260 situ was higher (P = .019) while the rate of invasive breast cancer was lower (P < .001) for FFDM com

261 effect of smoking on the risk of developing invasive breast cancer was modified significantly by obe

262 Overall the risk of invasive breast cancer was not associated with lifetime

263 ment of Premenopausal Women With Early-Stage Invasive Breast Cancer was reviewed for developmental ri

264 ctors (and controlled for age), the PAR% for invasive breast cancers was 70.0% (95% confidence interv

265 >/=20 ng/mL), the adjusted ORs (95% CIs) for invasive breast cancer were 6.1 (2.4, 15.1) for women wi

266 years of follow-up, 2,112 incident cases of invasive breast cancer were ascertained (1,626 ER(+) and

267 ion person-years of follow-up, 7690 cases of invasive breast cancer were diagnosed.

268 Multivariable HRs (95% CIs) for primary invasive breast cancer were estimated with the use of Co

269 ociation Consortium, 25,571 white women with invasive breast cancer were genotyped for CHEK2*1100delC

270 years of follow-up, 3,378 incident cases of invasive breast cancer were identified.

271 A total of 39,888 patients with invasive breast cancer were included, 7793 of whom were

272 Patients with mammography-detected invasive breast cancer were more often treated with lump

273 Women with operable HER2-positive invasive breast cancer were randomly assigned (1:1) with

274 stage hormone (oestrogen) receptor-positive invasive breast cancer were randomly assigned to exemest

275 rs; median age, 59 years) with nonmetastatic invasive breast cancer were recruited and followed for u

276 men younger than 70 years with nonmetastatic invasive breast cancer were recruited from Columbia Univ

277 Women with a diagnosis of incident invasive breast cancer were typically consented and enro

278 At a median follow-up of 35 months, 11 invasive breast cancers were detected in those given exe

279 f 11.5 y (IQR: 10.1-12.3 y), 10,197 incident invasive breast cancers were diagnosed [3479 estrogen an

280 During follow-up (mean = 6.4 years), 1,843 invasive breast cancers were diagnosed.

281 of 13 years of follow-up through 2010; 3388 invasive breast cancers were observed.

282 mean follow-up of 6.3 y, 20 incident primary invasive breast cancers were observed.

283 Cyclin E is altered in nearly a third of invasive breast cancers where it is a powerful independe

284 ed and overexpressed in approximately 20% of invasive breast cancers where it is associated with meta

285 e gene expression profiles of human DCIS and invasive breast cancer, which include novel genes regula

286 ere to study the progression from in situ to invasive breast cancer, which revealed that ductal carci

287 gery in Medicare patients with nonmetastatic invasive breast cancer who did not receive neoadjuvant c

288 ntified all patients in The Netherlands with invasive breast cancer who had an SLN biopsy before 2006

289 jor cancer centers with a first diagnosis of invasive breast cancer who identified themselves and all

290 593 consecutive patients with biopsy-proven invasive breast cancer who underwent breast MR imaging i

291 nts ages 29 to 85 years with stages I to III invasive breast cancer who underwent breast-conserving t

292 tients with ER-positive, lymph node-negative invasive breast cancer who underwent genomic testing fro

293 oved study was performed in 62 patients with invasive breast cancer who underwent multiagent NACT wit

294 ke in a cohort of 22,890 women with incident invasive breast cancer who were residents of Wisconsin,

295 patients with histopathologically confirmed invasive breast cancer who were undergoing NST were incl

296 mean age, 55 years; range, 23-83 years) with invasive breast cancers who had undergone MR imaging wer

297 We identified 509 patients with invasive breast cancer with a positive SLN who underwent

298 ic breast carcinoma is an aggressive form of invasive breast cancer with histological evidence of epi

299 Incident DCIS and invasive breast cancer within 1 year after mammography,

300 Similar to women with invasive breast cancer, women with CIS who are naturally